Influence of thymidylate synthase and p53 protein expression on clinical outcome in patients with colorectal cancer

International Journal of Colorectal Disease

Volumn 20, Issue 2, 2005, Pages 94-102

  Broll, R ^a   Busch, P ^a   Duchrow, M ^a   Oevermann, E ^a   Schwandner, O ^a   Farke, S ^a   Bruch, H P ^a   Windhovel U ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Immunohistochemistry; p53 Protein; Prognosis; Thymidylate synthase; Tumor recurrence

Indexed keywords

FLUOROURACIL; LEVAMISOLE; MONOCLONAL ANTIBODY; PROTEIN P53; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL NUCLEUS; CLINICAL FEATURE; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIOSENSITIVITY; TREATMENT OUTCOME; TUMOR CELL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BIOPSY; COLONOSCOPY; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSPECTIVE STUDIES; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 13644260462     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-004-0621-5     Document Type: Article

References (34)

1. American Cancer Society (1996) Cancer facts and figures. American Cancer Society, New York
2. National Institutes of Health (1990) NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. J Am Med Assoc 264:1444-1450
3. Drake JC, Voeller DM, Allegra CJ, Johnston PG (1995) The effect of dose and interval between 5-fluorouracil and leucovorin on the formation of thymidylate synthase ternary complex in human cancer cells. Br J Cancer 71:1145-1150 1:CAS:528:DyaK2MXmslCnsLk%3D
4. Peters GJ, van der Wilt CL, van Triest B, Codacci-Pisanelli G, Johnston PG, van Groeningen CJ, Pinedo HM (1995) Thymidylate synthase and drug resistance Eur J Cancer 31A:1299-1305 10.1016/0959-8049(95)00172-F
5. Rustum YM, Harstrick A, Cao S, Vanhoefer U, Yin MB, Wilke H, Seeber S (1997) Thymidylate synthase inhibitors in cancer therapy: Direct and indirect inhibitors. J Clin Oncol 15:389-400 1:CAS:528:DyaK2sXnsV2ltw%3D%3D
6. Kase S, Kubota T, Watanabe M, Takahara T, Takeuchi T, Yamaguchi H, Furukawa T, Teramoto T, Kodaira S, Ishibiki K (1993) The modulation by l -leucovorin of 5-fluorouracil antitumor activity on human colon carcinoma cells in vitro and in vivo. Surg Today 23:615-620 1:CAS:528:DyaK2cXhvVQ%3D
7. Pizzorno G, Sun Z, Handschumacher RE (1995) Aberrant cell cycle inhibition pattern in human colon carcinoma cell lines after exposure to 5-fluorouracil. Biochem Pharmacol 49:553-557 10.1016/0006-2952(94)00444-Q
8. Johnston PG, Liang CM, Henry S, Chabner BA, Allegra CJ (1991) Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. Cancer Res 51:6668-6676 1:CAS:528:DyaK38XhvFClsQ%3D%3D
9. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA, Allegra CJ (1994) The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12:2640-2647
10. Benhattar J, Cerottini JP, Saraga E, Metthez G, Givel JC (1996) p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 69:190-192 10.1002/(SICI)1097-0215(19960621)69:3<190::AID-IJC7>3.3.CO;2-X
11. Nabeya Y, Loganzo F, Maslak P, Lai L, de Oliveira AR, Schwartz GK, Blundell ML, Altorki NK, Kelsen DP, Albino AP (1995) The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Cancer 64:37-46 1:CAS:528:DyaK2MXltlels7Y%3D
12. Luna-Perez P, Arriola EL, Cuadra Y, Alvarado I, Quintero A (1998) p53 protein overexpression and response to induction chemoradiation therapy in patients with locally advanced rectal adenocarcinoma. Ann Surg Oncol 5:203-208 1:STN:280:DyaK1c3mvVKgtg%3D%3D
13. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810
14. O'Connor PM, Jackman J, Jondle D, Bhatia K, Magrath I, Kohn KW (1993) Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res 53:4776-4780 8402660
15. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage Cancer Res 51:6304-6311 1:CAS:528:DyaK38XhvFSltg%3D%3D
16. Lee Y, Chen Y, Chang LS, Johnson LF (1997) Inhibition of mouse thymidylate synthase promoter activity by the wild-type p53 tumor suppressor protein. Exp Cell Res 234:270-276 10.1006/excr.1997.3605
17. Bruch HP, Schwandner O, Keller R, Farke S, Schiedeck THK (2003) Surgical therapy for rectal cancer. Chirurgia 74:905914 10.1007/s00104-003-0735-2
18. Sterk P, Kasperk R, Opitz T, Schubert F, Klein P (2000) Vascular organization in the mesorectum: Angiography of rectal resection specimens. Int J Colorectal Dis 15:225-228 10.1007/s003840000237
19. Herfarth C, Runkel N (1994) Surgical standards in primary colorectal carcinoma. Chirurgia 65:514-523 1:STN:280:ByuA2svit1U%3D
20. Hermanek P, Sobin LH (eds) (1992) TNM classification of malignant tumours, 4th edn, 2nd rev. Springer, Berlin Heidelberg New York
21. Junginger T (Hrsg) (1997) Grundlagen der Chirurgie (G76): Leitlinien zur Therapie des Kolonkarzinoms. Demeter, Balingen
22. Junginger T (Hrsg) (1997) Grundlagen der Chirurgie (G78): Leitlinien zur Therapie des Rektumkarzinoms. Demeter, Balingen
23. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Garcia Y, Li J, Leichman L (1995) Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14:176-182
24. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M, Danenberg PV (1997) Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15:3223-3229 1:CAS:528:DyaK2sXmslOlu7o%3D
25. Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J, Romero A, Machiavelli M, De Lena M, Allegra CJ, Johnston P-G (2000) Thymidylate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 82:560-567 10.1054/bjoc.1999.0964
26. Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R, Banerjee D, Bertino JR, Groshen S, Leichman LP, Leichman CG (1998) p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: An analysis of response and survival. Clin Cancer Res 4:1243-1250 1:CAS:528:DyaK1cXjt1yiu70%3D
27. Chu E, Copur S, Jones KL, Khleif S, Voeller D, Maley GF, Maley F, Allegra CJ (1995) Thymidylate synthase regulates the translation of p53 mRNA. Proc Am Assoc Cancer Res 36:563
28. Kinsella AR, Smith D, Pickard M (1997) Resistance to chemotherapeutic antimetabolites: A function of salvage pathway involvement and cellular response to DNA damage. Br J Cancer 75:935-945. 1:CAS:528:DyaK2sXis1Wjur0%3D
29. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B (1994) Multifactorial analysis of p53 alteration in human cancer: A review. Int J Cancer 57:1-9
30. Edler D, Hallström M, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H (2000) Thymidylate synthase expression: An independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin Cancer Res 6:1378-1384. 1:STN:280:DC%2BD3c3jvFagtQ%3D%3D
31. Lenz HJ, Danenberg KD, Leichman CG, Florentine B, Johnston PG, Groshen S, Zhou L, Xiong YP, Danenberg PV, Leichman LP (1998) p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin Cancer Res 4:1227-1234. 1:STN:280:DyaK1c3mvVGqtQ%3D%3D
32. Takenoue T, Nagawa H, Matsuda K, Fujii S, Nita ME, Hatano K, Kitayama J, Tsuruo T, Muto T (2000) Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann Surg Oncol 7:193-198. 1:STN:280:DC%2BD3c3ltVGisw%3D%3D
33. Yamachika T, Nakanishi H, Inada K, Tsukamoto T, Kato T, Fukushima M, Inoue M, Tatematsu M (1998) A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 82:70-77. 1:CAS:528:DyaK1cXltlKgsg%3D%3D
34. Smith DR, Goh HS (1996) p53 and prognosis in colorectal cancer. Ann Acad Med Singapore 25:107-112. 1:STN:280:BymB28%2FktlY%3D